Alimera Sciences Inc., of Atlanta, reported that for the second quarter ended June 30, 2019, it recorded that its consolidated net revenue grew 2% to $10.9 million, compared to $10.7 million during the second quarter of 2018. U.S. net revenue was $7.3 million down 6% from $7.8 million during the same period in 2018. End user demand for its drug, Iluvien, for the treatment of diabetic macular edema, which represents units purchased by physicians and pharmacies from Alimera's U.S. distributors, decreased 4% in the quarter to 917 units compared to 955 units in the second quarter last year. International net revenue increased 21% to $3.5 million, compared to $2.9 million for the same period during 2018. The company's net loss was $5 million, compared to $4 million for the same period in 2018. As of June 30, 2019, Alimera had cash and cash equivalents of approximately $12.2 million. Its shares (NASDAQ:ALIM) fell 28% to close Tuesday at 64 cents.
Celgene Corp., of Summit, N.J., reported that its second quarter total revenue amounted to $4.4 billion, a 15% increase compared to $3.8 billion in the second quarter of 2018. Net income was $1.57 billion representing diluted earnings per share of $2.16 for the second quarter. Revlimid (lenalidomide) sales were $2.73 billion, an increase of 11% year-over-year with U.S. sales representing $1.81 billion and international sales $922 million, an increase of 14% and 6% year-over-year, respectively. Other product sales included: Pomalyst/Imnovid (pomalidomide) sales of $619 million, an increase of 22% year-over-year; Otezla (apremilast) sales of $493 million, representing an increase of 31%; and Abraxane (nab-paclitaxel) sales were $316 million, representing an increase of 30% over the comparable period last year. Celgene ended the quarter with approximately $9.3 billion in cash, cash equivalents, marketable debt securities and publicly-traded equity securities. The company's shares (NASDAQ:CELG) closed Tuesday at $92.61 down 0.41%.
Incyte Corp., of Wilmington, Del., said for the second quarter, net product revenues of Jakafi (ruxolitinib) were $410 million as compared to $346 million for the same period in 2018, representing 18% growth. Net product revenues of Iclusig (ponatinib) were $24 million for the quarter. Ex-U.S. product royalties from sales of Jakavi, which had been out-licensed to Novartis AG, of Basel, Switzerland, were $57 million and $47 million for the second quarters 2019 and 2018, respectively; royalties from the company's rheumatoid arthritis, drug Olumiant (baricitinib), licensed to Eli Lilly and Co., of Indianapolis, totaled $19 million compared to $9 million in the 2018 second quarter. Total revenues amounted to $530 million versus $522 million in the comparable period last year. The company posted net income of $105 million, or 49 cents per basic and 48 cents per diluted share, as compared to net income of $52 million, or 25 cents per basic and $0.24 per diluted share for the same period last year. The company had $1.7 billion in cash, equivalents and marketable securities at the end of the reporting period. Incyte's shares (NASDAQ:INCY) rose $5.17 on Tuesday to close at $85.43.
Neurocrine Biosciences Inc., of San Diego, reported that for the second quarter, total revenue, mainly generated from sales of its drug, Ingrezza (valbenazine), for the treatment of adults with tardive dyskinesia, was $183.6 million ($322 million for six-month period) compared to $96.9 million and $168 million for the same periods in 2018. The company reported net income of $51.3 million, or $0.54 diluted earnings per share, compared to a net loss of $5.9 million, or $0.07 net loss per share, for the same period in 2018. The increase was attributed to Ingrezza net product sales growth and a $21 million unrealized gain on the company's Voyager Therapeutics Inc., of Cambridge, Mass., equity investment. For the six months period, a net loss of $50.8 million was recorded, or $0.56 net loss per share, compared to a net loss of $47.7 million, or $0.53 net loss per share, for the same period in 2018. The company closed the period with cash, cash equivalents and short-term investments of $766.5 million. Neurocrine's shares (NASDAQ:NBIX) jumped $8.98 on Tuesday to close at $95.95.